CYP 3.85% 50.0¢ cynata therapeutics limited

Valueformoney: "...I get the feeling they will go at it alone...

  1. 11,577 Posts.
    lightbulb Created with Sketch. 509
    Valueformoney: "...I get the feeling they will go at it alone and I would have preferred a partnership mainly to expedite the trial." And:
    "I do think that the company has not showed strong recruitment rate capabilities and you never know.... 2022 will be telling and I am looking forward to MEND and DFU studies' results along with other key milestones."

    Valueformeney/others: In my opinion (correctly or wrongly!) CYP's current management set-up will simply NOT be capable to run that kind of envisaged trial in the USA without a solid partner that would need to help them a LOT in that not easy to navigate market!!
    Therefore, I would kind of "right-off" that project for the coming year (IF Cynata really plans to go it alone!!).

    On the other hand, to me key to a more decent share-price will be primarily the DFU project and potentially also MEND, of course. CYP should at least be able to push those forward with a bit more of purpose one could expect...

    Long-term holders have most certainly not seen many positives in holding onto CYP over the years. Hopefully, 2022 will finally see the CYP share-price at least above the A$ 1.00 mark again.... Time will tell.

    Best of luck to all CYP holders.

watchlist Created with Sketch. Add CYP (ASX) to my watchlist
(20min delay)
Mkt cap ! $71.63M
Open High Low Value Volume
52.0¢ 53.0¢ 50.0¢ $176.1K 343.8K

Buyers (Bids)

No. Vol. Price($)
4 14934 50.0¢

Sellers (Offers)

Price($) Vol. No.
51.5¢ 2000 1
View Market Depth
Last trade - 16.10pm 26/11/2021 (20 minute delay) ?
-0.020 ( 2.88 %)
Open High Low Volume
53.5¢ 53.5¢ 50.5¢ 107775
Last updated 15.35pm 26/11/2021 (live) ?
CYP (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.